{"id":180572,"date":"2026-02-13T04:15:21","date_gmt":"2026-02-13T09:15:21","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180572"},"modified":"2026-02-13T04:15:21","modified_gmt":"2026-02-13T09:15:21","slug":"earnings-summary-lupin-limited-reports-26-4-revenue-growth-in-third-quarter-fy2026","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-summary-lupin-limited-reports-26-4-revenue-growth-in-third-quarter-fy2026\/","title":{"rendered":"Earnings Summary &#8211; Lupin Limited Reports 26.4% Revenue Growth in Third Quarter FY2026"},"content":{"rendered":"\n<p><strong>Lupin Limited (NSE: LUPIN)<\/strong> is a global pharmaceutical company specializing in branded and generic formulations, biotechnology, and active pharmaceutical ingredients. The company reported record quarterly sales in the United States and double-digit growth across multiple international regions for the period ending December 31, 2025. The stock closed at \u20b92,208.70, a 0.11% decrease on the reporting day, implying a market capitalization of \u20b91,00,839.12 crore.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Quarterly Results<\/strong><\/h2>\n\n\n\n<p>Net sales reached \u20b971,005 million, a 26.4% year-over-year increase and 3.9% sequential growth. EBITDA for the period was \u20b923,766 million with a margin of 33.5%, up 840 basis points compared to the year-ago quarter. Profit after tax stood at \u20b911,805 million, a 37.4% increase over the same period last year.<\/p>\n\n\n\n<p>Results included a net exceptional item provision of \u20b94,266 million. Profit after tax decreased 20.5% from the \u20b914,848 million reported in the second quarter. Gross profit reached \u20b952,224 million with a margin of 73.5%. Material costs were 26.5% of sales, while personnel costs accounted for 16.1%.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Annual Performance Context<\/strong><\/h2>\n\n\n\n<p>For the first nine months of fiscal year 2026, Lupin recorded net sales of \u20b9200,956 million, a 20.8% increase over the prior year. Gross profit reached \u20b9146,208 million, a 27.4% improvement compared to the same period in fiscal 2025.<\/p>\n\n\n\n<p>EBITDA rose 50.3% to \u20b959,885 million, yielding a margin of 29.8%. Net income grew 54.3% to \u20b938,725 million. These figures indicate an upward trend in performance compared to the previous fiscal year across major financial metrics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Business and Operations Update<\/strong><\/h2>\n\n\n\n<p>The U.S. market recorded revenue of \u20b931,132 million, a 54.0% year-over-year growth supported by the launch of gRisperdal Consta. India formulation sales grew 5.6% year-over-year to \u20b920,387 million, while emerging markets rose 42.4%. Global API sales declined 24.1% to \u20b92,195 million.<\/p>\n\n\n\n<p>Research and development investment was \u20b95,352 million, or 7.5% of sales. Nagpur Unit-I received &#8220;No Action Indicated&#8221; status, and Pune Biotech received BLA approval. The company received one ANDA approval and launched three products during the quarter, bringing its total U.S. generic product count to 149.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Forward Outlook<\/strong><\/h2>\n\n\n\n<p>Managing Director Nilesh Gupta stated the company is &#8220;on track to deliver a strong close to FY26&#8221;. Strategic priorities include filing 10 to 15 ANDAs this fiscal year and completing 20 complex product launches by 2028. Long-term goals involve launching over 100 new products by fiscal 2031.<\/p>\n\n\n\n<p>Targets include a 65% revenue share from complex products by 2031 and filing three biosimilars in regulated markets by 2028. No specific quantitative guidance for future revenue or net profit was issued beyond these strategic objectives.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Performance Summary<\/strong><\/h2>\n\n\n\n<p>Lupin Limited\u2019s third-quarter results involved revenue growth in formulations markets and expansion in year-over-year EBITDA margins. Growth in the U.S. and emerging markets offset revenue declines in the API segment. The company maintains a negative net debt position of \u20b928,793 million while continuing investments in its complex generics pipeline.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lupin Limited (NSE: LUPIN) is a global pharmaceutical company specializing in branded and generic formulations, biotechnology, and active pharmaceutical ingredients. The company reported record quarterly sales in the United States and double-digit growth across multiple international regions for the period ending December 31, 2025. The stock closed at \u20b92,208.70, a 0.11% decrease on the reporting [&hellip;]<\/p>\n","protected":false},"author":2396,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747],"tags":[3187,16406,10162],"class_list":["post-180572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-biotechnology","tag-lupin","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":145655,"url":"https:\/\/alphastreet.com\/india\/lupin-limited-q4fy23-earnings-story\/","url_meta":{"origin":180572,"position":0},"title":"Lupin Limited Q4FY23 Earnings Story","author":"Karan_Singh","date":"May 10, 2023","format":false,"excerpt":"Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin Limited. The firm\u00a0is a worldwide leader in the Anti-TB and Cephalosporins segments and has a substantial presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, and Central Nervous system markets,\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":166808,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q3fy25-39-rise-in-profits\/","url_meta":{"origin":180572,"position":1},"title":"Lupin Ltd Q3FY25; 39% rise in Profits","author":"Chirag Gupta","date":"February 12, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168697,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q4fy25-112-rise-in-profits\/","url_meta":{"origin":180572,"position":2},"title":"Lupin Ltd Q4FY25; 112% rise in Profits","author":"Chirag Gupta","date":"June 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143124,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-lupin-limited-for-q3-fy23\/","url_meta":{"origin":180572,"position":3},"title":"Earnings Summary Of Lupin Limited For Q3 FY23","author":"Hardik Bhandare","date":"March 1, 2023","format":false,"excerpt":"Lupin Limited is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1968 and has operations in over 100 countries. Lupin is primarily engaged in the development, manufacture, and marketing of generic and branded pharmaceuticals, biosimilars, and specialty pharmaceuticals. The company has a diversified portfolio of products\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":163810,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1fy25-78-rise-in-profits\/","url_meta":{"origin":180572,"position":4},"title":"Lupin Ltd Q1FY25; 78% rise in Profits","author":"Chirag Gupta","date":"August 13, 2024","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-87.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-87.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-87.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-87.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-87.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-87.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":160871,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q4fy24-52-rise-in-profits\/","url_meta":{"origin":180572,"position":5},"title":"Lupin Ltd Q4FY24; 52% rise in Profits","author":"Chirag Gupta","date":"May 6, 2024","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-36.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-36.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-36.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-36.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-36.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-36.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2396"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180572"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180572\/revisions"}],"predecessor-version":[{"id":180577,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180572\/revisions\/180577"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}